Our scientific highlights
To help you navigate the wealth of abstracts, posters and sessions available, we’ve compiled our own Scientific Highlights, covering some of the most interesting sessions at the EADV Congress 2018.
Highlights by day – Wednesday 12 September
The day before the Congress begins in earnest is dedicated to subspecialty society meetings, a networking symposium and of course the opening plenary lecture, delivered this year by esteemed astrophysicist, Professor Thomas Boller (Garching, Germany). His opening presentation on Limits of the universe: From the beginning to the end is sure to propel expansive thinking and set the tone for the coming Congress.
A key meeting we’ve selected as a highlight considers the topic of hidradenitis suppurativa.
EHSF - European Hidradenitis Suppurativa Foundation (Room 252AB, 13:30 - 17:30)
- mTOR - a novel cascade in the pathogenesis of AI? – Dr Anke König
- Is there a role for specific biomarkers in HS? – Francesca Prignano MD, Ph
- Questionnaire-based epidemiological study of hidradenitis suppurativa in Japan revealing different characteristics from Westerners – Tadashi Terui MD, PhD
- Psychological traits in hidradenitis suppurativa and the factors that determine them – Dr Ermina Ofidou
- The new technologies in the study of hidradenitis suppurativa – Dr Giovanni Damiani
- Medical infrared thermography: a new promising imaging technique to assess hidradenitis suppurativa lesions – Dr Farida Benhadou
- Hidradenitis Suppurativa clinical subcategories: response to treatment – Dr Dunja Vekic
- Impact of comorbidities of HS patients on treatment choice and outcomes – Dr Karen Manuelyan
- Hidradenitis suppurativa and oral implications – Dr Giovanni Damiani
- Hidradenitis suppurativa and antibiotic resistance: state of art – Dr Graziana Amendolagine
- Can targeted HS antibiotherapy avoid mastectomy in granulomatous mastitis? – Delage Maïa MD
- Brazilian experience in hidradenitis suppurativa surgery: the role of cotton dressing –Edileia Bagatin MD, PhD
- Laser assisted photodynamic therapy for HS – Dr Yuval Hilerowicz
- Pro/contra: Antibiotics vs. biotherapies in HS: antibiotics – Dr Olivier Join-Lambert
- Pro/contra: Evidence of genuine epithelial inflammation in hidradenitis suppurativa emerges the need of targeted anti-inflammatory treatment – Professor Dr Christos C. Zouboulis
Highlights by day – Thursday 13 September
Keynote speaker Tilo Biedermann (Munich, Germany), is sure to bring his wealth of pan-European experience to the first keynote lecture on Thursday morning (PL-A03 Skin infection and atopic dermatitis). He will examine research undertaken on cutaneous immune reactions including chronic inflammatory skin diseases in preclinical models and investigations in basic science as well as in translational research.
Sessions of interest on Thursday morning include:
Spotlights 1 (Grand Amphitheatre, 08:00 - 11:15)
This short presentation looks at some of the key areas defined in new treatments of psoriasis.
- D1T01.1A Psoriasis treatment options in 2018 – Professor Antonio Costanzo , Rome, Italy
Hidradenitis suppurativa (Amphi Havane, 09:45 - 11:15)
- D1T04.2A Clinical spectrum – Dr Emilie Sbidan, Michigan, USA.
- D1T04.2B Microbiome and antibiotics – Professor Gregor B.E. Jemec , Charlottenlund, Denmark
- D1T04.2C Non-surgical therapies – Professor Dr Christos C. Zouboulis , Dessau, Germany
- D1T04.2D Surgical therapies – Professor Dr Klemens Rappersberger , Vienna, Austria
Targeting the JAK/STAT pathway: Clinical perspectives (Expert Forum, Room 242AB, 08:00 - 09:30)
This session considers how to gain a deeper understanding of JAK/STAT pathways and how that knowledge can be applied in a clinical setting.
- D1T09.1A The clinical impact of the JAK/STAT pathway – Dr Kamran Ghoreschi, Tübingen, Germany
- D1T09.1B Psoriasis and rheumatoid arthritis – Professor Hervé Bachelez , Paris, France
- D1T09.1C Alopecia areata and vitiligo – Brett King MD, PhD, Yale, USA
- D1T09.1D Atopic dermatitis – Professor Thomas Werfel, Hannover, Germany
Psoriasis 1 (Grand Amphitheatre, 13:15 - 14:45)
A look at some different and less common presentations of psoriasis is considered during this session.
- D1T01.2A Clinical manifestations and pitfalls – Professor Dr Jan Christoph Simon, Leipzig, Germany
- D1T01.2B Pathogenesis: Insights into treatment decisions and paradoxic reactions – Professor Michel Gilliet, Lausanne, Switzerland
- D1T01.2C Diagnosis and management of palmoplantar psoriasis – Professor Dr Lajos Kemény, Szeged, Hungary
- D1T01.2D Scalp and nail psoriasis: Diagnosis and treatment – Professor Bertrand Richert, Brussels, Belgium
Psoriasis 2 (Grand Amphitheatre, 15:00 - 16:30)
This session considers some of the newer treatments available in the psoriasis paradigm, including a look at TNF antagonists and interleukin inhibitors.
- D1T01.3A Topical and photo-therapies – Dr Wolfram Hoetzenecker, Zurich - Switzerland
- D1T01.3B Classical systemic therapies and combinations – Professor Rolland Gyulai, Pécs, Hungary
- D1T01.3C TNF antagonists – Dr Curdin Conrad, Lausanne, Switzerland
- D1T01.3D IL-17 and IL-23 antagonists – Professor Jonathan Barker, London, United Kingdom
Highlights by day – Friday 14 September
Today, we’ll be considering one of the key practical clinical sessions on psoriasis.
Psoriasis (Training and Educational Forum, Room 351, 08:00 - 09:30)
- D2T11.1A Clinics, spectrum and pathophysiology – Professor Jörg C. Prinz, Munich, Germany
- D2T11.1B Differential diagnosis and pitfalls – Professor Paolo Gisondi, Verona, Italy
- D2T11.1C Psoriasis and the metabolic syndrome – Dr James G. Krueger, New York, United States
- D2T11.1D Management of psoriasis: Topical therapy and phototherapy – Professor Wolf-Henning Boehncke, Geneva, Switzerland
Highlights by day – Saturday 15 September
One of the key sessions we’ll be looking out for today comes from Professor Leena K. Bruckner-Tuderman (Freiburg, Germany), presenting in Plenary B on Saturday (PL-C07 ESDR Plenary Lecture: Skin fragility syndromes). Her research deals with the biology of basement membranes and the extracellular matrix, along with molecular genetics to understand the disease mechanisms of skin disorders, and the development of biologically valid therapies.
Highlights by day – Sunday 16 September
With therapy options for medical dermatology continually evolving, Sunday is a good day to consider some of the most interesting posters which have been presented over the previous days at Congress. We’ll be looking for, and reporting on, some of the ground-breaking data presented on how biologics are being considered the new standard of care, and how biosimilars are also becoming a prevalent alternative. As research expands around newer therapies such as IL-17 and IL-23 pathways we’ll examine how treatment options fit together. We’ll consider how varying mode of actions interact and their place in the treatment landscape, as well as reflecting on the EADV Congress as a whole.